|
|||
| May 27, 2026 • Vol. 1, Issue 6 • Clinical & News Edition | |||
|
Contact & Correspondence
We welcome inquiries, tips, letters to the editor, and article ideas from the MBS community. Reach us at [email protected]. Your submissions help shape what we cover. |
Coming Soon
Invited surgeon commentaries are forthcoming. If you are interested in contributing a perspective or editorial on a topic relevant to metabolic and bariatric surgery, please contact us at [email protected]. |
Bariatric Surgery in CKD Patients Cuts End-Stage Renal Disease Risk in Half and More Than Doubles the Rate of Kidney TransplantPresented at ASMBS 2026 Annual Meeting, San Antonio, TX. May 5, 2026.
A propensity-matched analysis presented at the ASMBS 2026 Annual Meeting offers the most direct large-scale comparison of surgical versus non-surgical management in patients carrying both obesity and chronic kidney disease. Investigators matched 4,481 metabolic and bariatric surgery patients one-to-one with non-surgical controls from a large real-world database, following both cohorts for end-stage renal disease, dialysis initiation, kidney transplantation, major cardiovascular events, and all-cause mortality across the full observation period. The surgical cohort cut its rate of end-stage kidney disease by more than half (5.9% versus 11.9%) and was approximately 60% less likely to require dialysis (4.1% versus 9.0%). The most clinically striking finding involved transplant access: patients who underwent bariatric surgery were more than twice as likely to receive a kidney transplant (4.6% versus 2.2%), a finding that inverts the conventional assumption that obesity-related CKD is a trajectory toward renal failure, not transplant eligibility. Major cardiovascular events and all-cause mortality were halved in the surgical group as well. The data support treating metabolic surgery as a systemic disease modifier in CKD rather than a weight reduction procedure, and point toward earlier surgical referral conversations between bariatric programs and nephrology colleagues. Key Finding
4,481 matched pairs. ESRD: 5.9% vs. 11.9%. Dialysis: 4.1% vs. 9.0%. Kidney transplant: 4.6% vs. 2.2%; surgical patients more than twice as likely to receive a transplant. MACE and all-cause mortality also halved. ASMBS 2026, San Antonio. |
Prior GLP-1 Therapy Does Not Compromise Bariatric Surgery Outcomes: Sequential Treatment Drives Total Weight Loss Past 25%Presented at ASMBS 2026 Annual Meeting, San Antonio, TX (NYU Grossman School of Medicine). May 5, 2026.
As GLP-1 receptor agonists become a near-universal first step in obesity management, a practical clinical question has emerged for surgical teams: does prior pharmacotherapy diminish what bariatric surgery can accomplish? New data from NYU Grossman School of Medicine, presented at the ASMBS 2026 Annual Meeting, answer it. Patients who received semaglutide or tirzepatide before surgery lost approximately 8% of their total body weight during the medication phase, then achieved additional substantial weight loss post-operatively, exceeding 25% total body weight loss following RYGB and approximately 20% following sleeve gastrectomy. Patients who proceeded directly to surgery without prior GLP-1 exposure lost only 2% to 3% more in the post-operative period, a negligible difference. Surgeons fielding this question from patients, payers, and referring physicians (who assume that GLP-1-induced weight loss and bariatric surgery draw from the same physiological reserve) now have a clear answer: the data say otherwise. The sequential model (pharmacotherapy to optimize metabolic status, followed by surgery to deliver durable structural and hormonal change) stands as a rational pathway, particularly for higher-risk patients who benefit from preoperative metabolic stabilization before an elective procedure. Sequential Approach
GLP-1 pre-treatment (semaglutide or tirzepatide): ~8% TWL before surgery. Post-RYGB total: >25%. Post-sleeve total: ~20%. Patients going straight to surgery lost only 2-3% more post-operatively. Prior GLP-1 use does not compromise surgical outcomes or blunt the operative benefit. |
Metabolic Surgery Induces MASH Cirrhosis Regression in One-Third of Patients: Paired Biopsy Evidence Challenges End-Stage DogmaLaique S et al., “Can Metabolic Surgery Regress MASH Cirrhosis? Evidence From Paired Biopsies.” Presented at Digestive Disease Week (DDW) 2026, Washington, DC. May 2026.
Cirrhosis has long been classified in clinical practice as a fixed, irreversible endpoint, the threshold beyond which liver transplantation represents the only curative path. New data from Cleveland Clinic challenge that framing with paired biopsy evidence. In a retrospective cohort study of patients with biopsy-proven compensated metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis who underwent metabolic and bariatric surgery, investigators obtained paired liver biopsies at the time of the index operation and again at follow-up, with a median interval exceeding six years. Among the 30 patients evaluated, one in three demonstrated regression of cirrhosis (defined as histologic improvement to a less advanced fibrosis stage) on the follow-up specimen. Dr. Sobia Laique, Director of the Multidisciplinary MASLD Center at Cleveland Clinic, described the results as evidence that cirrhosis should no longer be treated categorically as a fixed end-stage condition. The implications for patient selection extend in two directions: patients with compensated MASH cirrhosis who have historically been deferred from bariatric surgery on hepatic risk grounds may, in certain cases, stand to gain from it; and the long follow-up gives these findings a durability that short-term studies cannot. Cleveland Clinic has established a dedicated metabolic biorepository of patient tissue and biospecimens, aimed at developing a precision approach to patient selection in advanced liver disease by identifying biological predictors of cirrhosis regression before surgery. Histologic Evidence
30 patients with biopsy-proven compensated MASH cirrhosis. Median follow-up: >6 years. Cirrhosis regression on paired biopsy: 1 in 3 patients. Biorepository established to identify biological predictors of response. DDW 2026, Washington, DC. |
Bariatric Surgery Reduces Cancer Risk and Mortality in Women but Not Men: Insulin Level and Genetics Define Who Benefits MostPost hoc analysis of the Swedish Obese Subjects (SOS) Study. PLOS Medicine. May 25, 2026.
A post hoc analysis of the Swedish Obese Subjects study (one of the longest-running prospective investigations of bariatric surgery outcomes in the world) finds that the cancer risk reduction associated with surgical weight loss is not distributed equally between sexes. Drawing on data from more than 4,000 participants (approximately half of whom underwent bariatric surgery with the remainder serving as matched controls), the investigators examined long-term cancer incidence and cancer-related mortality stratified by sex, baseline insulin level, and genetic profile. Surgical weight loss was associated with meaningfully lower cancer risk and cancer-related mortality in women, with no comparable protective signal observed in men across the same follow-up horizon. The sex-specific pattern was not explained by differences in the magnitude of weight loss between male and female surgical patients. Biological interactions emerged as the dominant mediators: among women, the cancer risk reduction was most pronounced for breast and gynecological cancers, and was most strongly concentrated in patients with high pre-surgical insulin levels and specific genetic variants associated with insulin metabolism. The data point to something operationally useful for MBS programs. Patients most likely to derive cancer-protective benefit from bariatric surgery may be identifiable preoperatively through metabolic and genomic characterization, a framework that could sharpen surgical referral criteria and support the case for surgery in women with elevated insulin who sit at the margins of standard eligibility thresholds. Precision Oncology Signal
4,000+ SOS participants. Cancer risk and mortality reduction: women only; no significant protective effect in men. Strongest benefit: breast and gynecological cancers. Effect modifiers: high baseline insulin + specific genetic variants. PLOS Medicine, May 25, 2026. |
Retatrutide Phase 3 TRIUMPH-1: 28.3% Mean Weight Loss at 80 Weeks: First Drug Trial to Document Surgery-Level Weight Reduction at Population ScaleEli Lilly and Company. TRIUMPH-1 Phase 3 Trial Results. investor.lilly.com. May 21, 2026.
Eli Lilly released Phase 3 data from TRIUMPH-1 on May 21, 2026, and the results represent a threshold crossed in obesity pharmacology. The randomized, double-blind, placebo-controlled trial enrolled 2,339 participants and evaluated three doses of retatrutide (4 mg, 9 mg, and 12 mg); all arms met primary and key secondary endpoints. On the 12 mg dose, participants lost a mean of 28.3% of their total body weight over 80 weeks, approximately 70 pounds, compared with 2.2% in the placebo group. Among participants on the highest dose, 45.3% achieved at least 30% total body weight loss. In a trial extension enrolling participants with baseline BMI of 35 or higher who continued therapy through 104 weeks, mean total body weight loss reached 30.3%, or an average of 85 pounds. Retatrutide is a first-in-class triple hormone receptor agonist, activating receptors for GIP, GLP-1, and glucagon in a single molecule. The 30% weight loss benchmark has been associated, until now, almost exclusively with bariatric surgery, and the TRIUMPH-1 data reach it not in a small cohort but across 2,339 participants in a pivotal registration trial. Lilly has guided for an NDA submission to the FDA in the fourth quarter of 2026; under standard review, approval would be expected in late 2027 or early 2028. A drug has now matched surgical weight loss benchmarks in a registration trial. The harder question is how bariatric programs articulate what surgery provides that pharmacotherapy doesn't: durable disease remission, anatomical restructuring, and long-term multidisciplinary follow-up. TRIUMPH-1 Data
12 mg dose: 28.3% mean TWL (~70 lbs) at 80 weeks. 45.3% of participants achieved ≥30% weight loss. 104-week extension (BMI ≥35): 30.3% mean TWL (~85 lbs). All doses met primary and key secondary endpoints. NDA submission: Q4 2026. Approval timeline: late 2027 or Q1 2028. |
EASO 2026 Pharmacotherapy Framework Published in Nature Medicine: European Consensus Now Mirrors U.S. Guidance, Elevating Semaglutide and Tirzepatide as First-LineEuropean Association for the Study of Obesity (EASO). Nature Medicine. 2026. DOI: 10.1038/s41591-026-04397-4. May 13, 2026.
The European Association for the Study of Obesity has published the 2026 update of its living pharmacotherapy framework in Nature Medicine, providing European clinicians with a systematically derived algorithm for aligning individual patient profiles with available obesity medications. The 2026 version incorporates a systematic literature review and network meta-analysis of 62 randomized controlled trials of medications approved in Europe, with updated data on body weight reduction and liver disease outcomes, two domains where the evidentiary landscape has expanded substantially since the prior iteration. Semaglutide and tirzepatide are designated as effective first-line pharmacotherapies for obesity and its related complications under the new guidance. The 2026 EASO update arrives one issue after the joint TOS/OMA/OAC guidance published in March 2026 and covered in Issue 5, and the convergence between the American and European frameworks is now unambiguous: both name semaglutide and tirzepatide first-line; both reject the framing of pharmacotherapy as lifestyle-adjunctive; and both call for individualized medication selection based on patient comorbidity profile rather than any fixed therapeutic sequence. One methodologically notable feature of the EASO document is its living design: the framework is intended to be updated regularly as new trial data emerge, a structure that reflects the pace of development in this field. The transatlantic consensus makes clear where the evidence now stands, and means that most patients will have tried pharmacotherapy before arriving at a surgical consultation. Transatlantic Consensus
62 RCTs analyzed. Semaglutide and tirzepatide: first-line for obesity and complications. Comorbidity-guided algorithm: patient profile drives medication selection, not fixed sequence. Living document designed for ongoing update. Mirrors March 2026 TOS/OMA/OAC guidance (Issue 5). Nature Medicine, May 13, 2026. |
Experimental “Trojan Horse” Obesity Drug Delivers a Metabolic Payload into Cells Via GLP-1 Signaling: Five Pathways, One MoleculeMüller TD et al., Helmholtz Munich. ScienceDaily. May 6, 2026.
A research group at Helmholtz Munich led by Prof. Timo D. Müller has published preclinical results for an experimental obesity drug candidate built on a delivery strategy that differs fundamentally from every approved GLP-1 agent. Rather than acting exclusively at cell surface receptors, the molecule uses GLP-1 and GIP receptor signaling as a cellular entry mechanism: the incretin signal opens the door, and a PPAR-activating payload enters with it. The compound simultaneously activates two receptors on the cell surface (GLP-1R and GIPR) and three PPAR nuclear receptors from within the cell, engaging five distinct metabolic pathways through a single hybrid molecule. The core pharmacological advantage is dosing precision: because the PPAR-activating component travels into target cells via the incretin signal rather than being administered systemically, it can be effective at a dose orders of magnitude lower than would be required through independent systemic delivery, significantly reducing the potential for off-target toxicity that has historically complicated systemic PPAR agonism. In mouse models, the compound outperformed existing treatments on appetite suppression, body weight reduction, and blood glucose control. This research is preclinical, and the path to a clinical candidate involves substantial further work. The conceptual framework (using receptor-mediated cellular entry to achieve targeted intracellular pharmacology) departs from the surface-receptor model that has defined obesity pharmacology since the GLP-1 era began, and may point toward a next generation of obesity drugs designed around tissue-specific intracellular targeting. Mechanism
GLP-1R + GIPR activation at cell surface; 3 PPAR nuclear receptors engaged intracellularly via the same signal. PPAR dose: orders of magnitude lower than systemic administration. Mouse models: superior weight loss, appetite suppression, glycemic control vs. GLP-1 monotherapy. Status: preclinical. Helmholtz Munich, ScienceDaily, May 6, 2026. |
NIH: Oral Small-Molecule GLP-1 Drugs Suppress Pleasure Eating Through a Deep Brain Reward Circuit. A Distinct Mechanism from Injectable AgentsNational Institutes of Health. NIH News Release. May 6, 2026.
An NIH-funded study has mapped a previously uncharted neural mechanism by which oral small-molecule GLP-1 receptor agonists (drugs like orforglipron, Foundayo) suppress food intake. Injectable GLP-1 peptides act primarily through peripheral satiety pathways and brainstem circuits. Oral nonpeptide GLP-1 agonists, the study finds, penetrate deeper brain structures and modulate a reward circuit that governs hedonic feeding, eating driven by pleasure and craving rather than caloric need. In mouse models, this mechanism produced measurable suppression of pleasure-seeking food intake that was distinct from the appetite reduction produced by injectable GLP-1 formulations. The reward circuit identified in the study is the same network implicated in substance use disorder, compulsive behavior, and reward dysregulation, areas of direct and long-standing concern for bariatric surgeons who track addiction transfer, cross-addiction, and disordered eating patterns in their post-operative populations. If the preclinical findings translate to humans, oral GLP-1 agents may carry a neurological and behavioral profile that differs meaningfully from injectable counterparts, with practical implications for patient selection, post-surgical medication management, and monitoring of patients with comorbid disordered eating or substance use history. The NIH investigators note this pathway may represent a broader avenue for treating reward processing dysfunction beyond obesity. The finding gives the oral-versus-injectable distinction a biological basis that practitioners are already navigating clinically in a rapidly evolving pharmacological landscape. Clinical Relevance for MBS
Oral GLP-1s penetrate deep brain reward circuits; injectable GLP-1s act primarily on peripheral and brainstem satiety pathways. Effect: suppression of hedonic (pleasure-driven) feeding. Same circuit implicated in substance use disorder and addiction. Implication: oral and injectable GLP-1s may have distinct behavioral profiles, relevant for post-bariatric addiction transfer monitoring. NIH News Release, May 6, 2026. |
FDA Approves Wegovy HD (Semaglutide 7.2 mg): Highest-Dose Injection Posts 20.7% Mean Weight Loss, 27.7% in Early RespondersNovo Nordisk A/S press release. BioSpace. 2026.
The FDA has approved a higher-dose formulation of semaglutide injection (Wegovy HD at 7.2 mg weekly) providing patients and prescribers with a more potent option within the existing Wegovy dosing architecture. The approval comes at a moment of intensifying competition: Eli Lilly’s tirzepatide (Zepbound) has consistently outperformed standard-dose Wegovy in comparative data, and the TRIUMPH-1 results for retatrutide covered in Section B push the pharmacological weight loss ceiling further still. Wegovy HD was evaluated in the STEP UP trial, in which participants achieved a mean total body weight loss of 20.7% at 72 weeks on the 7.2 mg dose, a meaningful advance from the 15% to 17% range reported for the standard 2.4 mg formulation. The cardiovascular SELECT trial data are preserved in the Wegovy HD labeling, maintaining the MACE reduction claim that distinguishes semaglutide from newer agents without completed long-term cardiovascular outcome data. A clinically significant subgroup finding emerged from the early responder analysis: patients classified as early responders to semaglutide lost a mean of 27.7% of their body weight at 72 weeks, approaching the lower range of bariatric surgical outcomes for sleeve gastrectomy. Approximately one in three participants on Wegovy HD achieved 25% or greater total body weight loss. Two things follow practically for MBS programs. Patients who have plateaued on standard-dose semaglutide have a well-characterized next pharmacological step before surgical consideration; and surgical candidates responding favorably to HD semaglutide preoperatively may present to the OR with meaningfully improved metabolic profiles, consistent with the sequential model supported by the NYU Grossman data in Section A. STEP UP Data
Wegovy HD 7.2 mg: 20.7% mean TWL at 72 weeks. Early responders: 27.7% mean TWL. Approximately 1 in 3 patients achieved ≥25% weight loss. SELECT cardiovascular MACE reduction data retained in labeling. |
Wegovy Pill Recommended for EU Approval: First Oral GLP-1 for Weight Management Clears European Regulators as Global Oral Market Takes ShapeNovo Nordisk A/S. GlobeNewswire. May 22, 2026.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended marketing authorization for Wegovy pill (once-daily oral semaglutide 25 mg) on May 22, 2026, making it the first oral GLP-1 receptor agonist recommended for approval for weight management in the European Union. The recommendation follows FDA approval of oral Wegovy earlier in 2026 and positions Novo Nordisk to compete in the rapidly forming global oral GLP-1 market on both regulatory fronts simultaneously. The EU label includes SELECT cardiovascular outcome data, a differentiated claim that oral competitors currently lack. The European Commission, which typically issues final marketing authorization within approximately two months of a positive CHMP opinion, is expected to act accordingly. The oral market is moving quickly. Novo Nordisk launched oral Wegovy (25 mg) in the U.S. in January 2026; Eli Lilly’s Foundayo (orforglipron) reached U.S. pharmacies in April 2026 at $149 per month out of pocket, with a distinctive convenience profile: no food, water, or timing restrictions, in contrast to the administration requirements for oral semaglutide. The CHMP recommendation gives Novo Nordisk a first-mover advantage in European oral GLP-1 that mirrors its injectable leadership, while Lilly’s orforglipron EU application is expected to follow. For MBS programs with international patient populations or European research collaborators, an oral GLP-1 option with a robust cardiovascular evidence base is now advancing toward European clinical availability, which could reshape pre-surgical pharmacotherapy protocols in European bariatric centers. EU Regulatory Advance
CHMP recommended marketing authorization: May 22, 2026. Oral semaglutide 25 mg: first oral GLP-1 for weight management in EU. SELECT MACE reduction data included in EU label. EC final decision expected within ~2 months. U.S. oral Wegovy: January 2026. Foundayo (orforglipron): April 2026 U.S. launch at $149/month. |
CMS Medicare GLP-1 Bridge Takes Effect July 1 at $50 Monthly Copay: A Structural Equity Gap Leaves the Lowest-Income Beneficiaries BehindThe Centers for Medicare and Medicaid Services has finalized details of the Medicare GLP-1 Bridge program, which will provide eligible Medicare Part D beneficiaries with access to approved GLP-1 obesity medications for a $50 monthly copayment beginning July 1, 2026, through December 31, 2027. Three medications are covered: orforglipron (Foundayo), injectable or oral Wegovy, and Zepbound (KwikPen formulation). Eligibility is broad by design: a BMI of 35 or greater automatically qualifies, and a BMI of 27 or greater with a cardiovascular comorbidity, prediabetes, or qualifying weight-related condition meets the threshold. CMS projects the program will provide access to GLP-1 obesity medications for millions of Medicare beneficiaries who have not previously had coverage for this indication. A structural equity concern runs through the program’s design and has drawn criticism from patient access advocates. Medicare beneficiaries enrolled in the Low Income Subsidy (a federal program that reduces or eliminates drug costs for the lowest-income Part D enrollees) cannot apply those LIS benefits toward their GLP-1 Bridge copayments. Because the bridge program operates outside the standard Part D benefit structure, the federal subsidy that exists precisely to protect the most financially vulnerable Medicare patients does not apply here. For a beneficiary near the LIS income ceiling, a $50 per-month copayment is not a trivial amount for a single medication. Meanwhile, the BALANCE Model (designed to expand GLP-1 access more broadly through Part D and Medicaid) has seen its Part D implementation delayed indefinitely, while Medicaid expansion advances in participating states. The treatment gap documented in the MBS literature remains structural. A bridge program that excludes its most cost-sensitive participants cannot close it. Access & Equity
July 1 to Dec 31, 2027: $50/month for Foundayo, Wegovy (injection or pill), Zepbound KwikPen. Eligibility: BMI ≥35 automatic; BMI ≥27 + qualifying comorbidity. Critical: LIS (low-income) beneficiaries cannot apply their federal subsidy to bridge copays. BALANCE Part D: delayed indefinitely. BALANCE Medicaid: advancing in participating states. |
Retatrutide Phase 3 Results Lift Eli Lilly and Force a Strategic Reckoning: The First Drug Trial Has Now Documented Surgery-Level Weight Loss at ScaleEli Lilly’s TRIUMPH-1 results, released May 21, moved the company’s shares materially higher and sent ripples across the obesity treatment market that extend well beyond any single session’s price action. The weight loss documented in the trial: 28.3% mean total body weight reduction on the 12 mg dose, with 45.3% of participants reaching or exceeding 30%. This represents a pharmacological milestone. The 30% threshold has historically appeared in the bariatric surgery literature as the benchmark for surgical adequacy; the fact that a pivotal registration trial of 2,339 participants has now cleared it at scale is a development the MBS community should engage with strategically rather than dismiss. Bank of America raised its price target on LLY to $1,251 (Buy) following the TRIUMPH-1 data, reflecting analyst confidence that the results reinforce Lilly’s lead position in obesity pharmacotherapy development. Lilly has guided for an NDA submission to the FDA in the fourth quarter of 2026; under standard review, approval would be expected in late 2027 or early 2028. Prediction market odds currently assign approximately 22% probability to a 2026 approval, correctly reflecting the timeline constraints of the regulatory pathway. The competitive pressure on Novo Nordisk is real but bounded: NVO lacks a triple agonist in its current pipeline and entered the week with the oral market launch advantage, but exited it having lost the pharmacological headline. TRIUMPH-1 doesn’t call for a defensive posture from bariatric programs. It calls for a clear-eyed acknowledgment that surgery and pharmacotherapy are heading toward complementary rather than competing roles, with surgery positioned as the durable, disease-modifying, and physiologically restructuring intervention that no drug has replicated. Market Watch
LLY surged on May 21 TRIUMPH-1 release. BofA raised target to $1,251 (Buy). NDA submission: Q4 2026 expected. FDA approval: standard review → late 2027 or Q1 2028. Prediction market: ~22% probability of 2026 approval. 45.3% of participants achieved ≥30% weight loss; first drug trial to match surgical benchmarks at registration scale. |
Novo Nordisk Executes on Two Fronts in One Week: Wegovy HD Approved in U.S., Wegovy Pill Advances to EU Approval RecommendationNovo Nordisk A/S press releases / BioSpace / GlobeNewswire. May 2026.
Novo Nordisk delivered its strongest two-week stretch of 2026, producing two independent regulatory catalysts that together rebuild competitive positioning after months of CagriSema-driven disappointment and guidance reductions. The FDA’s approval of Wegovy HD (semaglutide 7.2 mg) was followed on May 22 by a positive CHMP opinion recommending EU marketing authorization for Wegovy pill (oral semaglutide 25 mg), the first oral GLP-1 recommended for approval for weight management in Europe. NVO shares jumped approximately 3% in premarket trading on the day of the HD data release, with retail investor sentiment described as extremely bullish alongside high message volume on trading platforms. The SELECT cardiovascular outcome data included in both Wegovy HD and Wegovy pill labels remain NVO’s most durable competitive differentiator against agents without completed cardiovascular trials. In the U.S. oral GLP-1 market, Novo launched first (oral Wegovy, January 2026) but Eli Lilly’s Foundayo, reaching pharmacies in April 2026 at $149 per month without food or water restrictions, has drawn favorable attention for convenience. The CHMP recommendation gives Novo a first-mover advantage in European oral GLP-1 that mirrors its injectable leadership on that continent, while Lilly’s orforglipron EU application follows. At approximately $45 per share (ADR), NVO has recovered meaningfully from its late-2025 lows following the CagriSema data setback, and the dual May catalyst may mark a sentiment inflection. Heading into the second half of 2026: LLY leads on pipeline depth (retatrutide) and injectable performance; NVO leads on cardiovascular evidence and oral launch timing. Both are well-positioned as the obesity market accelerates. Novo Dual Catalyst Week
Wegovy HD (7.2 mg) FDA approved: 20.7% mean TWL. CHMP recommended EU Wegovy pill: May 22, 2026. NVO: ~+3% premarket on HD data; recovery from CagriSema-driven lows. SELECT MACE data in both labels: key competitive differentiator. LLY oral (Foundayo) advantage: no food, water, or timing restrictions. |
The Medicare GLP-1 Bridge: A Historic Policy Step With a Structural Blind Spot. What MBS Programs Need to Know Before July 1The Medicare GLP-1 Bridge program that takes effect July 1 is the most significant federal obesity coverage expansion in Medicare's history, and also a study in how policy design can embed inequity in the attempt to expand access. The architecture matters operationally for MBS programs and obesity medicine practices: it will directly influence which Medicare patients pursue or continue pharmacological treatment, which initiate or resume surgical consultation, and which remain in the treatment gap the program was designed to close. Three branded medications are covered under the bridge: orforglipron (Foundayo), Wegovy in injection or pill form, and Zepbound KwikPen. Eligibility is automatic at BMI 35 or higher, and available with a qualifying comorbidity at BMI 27 or higher. The equity problem centers on the Low Income Subsidy. LIS enrollees (Medicare's lowest-income Part D beneficiaries, whose drug costs are otherwise substantially reduced by federal subsidy) cannot apply their LIS benefits to bridge program prescriptions. They face the full $50 per month copay from personal income, because the bridge operates outside the standard Part D benefit structure. For a beneficiary near the LIS income ceiling, this is not a trivial amount. Meanwhile, BALANCE Model implementation in Medicare Part D (the mechanism that would have provided more comprehensive coverage through the existing benefit structure) remains indefinitely delayed. Medicaid implementation is advancing in participating states, but only 13 |
Kalshi: Take a position on the games you follow and earn if you’re right. No house, peer-to-peer, and cash out anytime. Start with a free $10 here. Put $10 to Work.